Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNY
stocks logo

SNY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.14B
+5.47%
0.798
+16.96%
10.12B
+2.27%
0.989
-3.22%
10.77B
+7.71%
0.000
-100%
Estimates Revision
The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -1.39% over the past three months. During the same period, the stock price has changed by 7.88%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.42%
In Past 3 Month
Stock Price
Go Up
up Image
+7.88%
In Past 3 Month
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 48.900
sliders
Low
58.00
Averages
63.50
High
69.00
Current: 48.900
sliders
Low
58.00
Averages
63.50
High
69.00
Oppenheimer
Trevor Allred
Outperform
maintain
$60 -> $62
2025-11-06
Reason
Oppenheimer
Trevor Allred
Price Target
$60 -> $62
2025-11-06
maintain
Outperform
Reason
Oppenheimer analyst Trevor Allred raised the firm's price target on Dianthus (DNTH) to $62 from $60 and keeps an Outperform rating on the shares. The firm notes Dianthus reported a Q3 net loss of $37M, in line with its $36M estimate. Oppenheimer's focus is narrowing onto CIDP, as claseprubart's Phase 3 enrollment looks to be garnering subjects from Sanofi's (SNY) riliprubart and other therapeutic options. The firm expects CIDP results to garner more investor attention.
Jefferies
Buy
initiated
€100
2025-10-27
Reason
Jefferies
Price Target
€100
2025-10-27
initiated
Buy
Reason
Jefferies assumed coverage of Sanofi with a Buy rating and EUR 100 price target, calling it the analyst's EU Pharma top pick. Valued at about a 15% discount to the sector, the firm believes the perception that Sanofi lacks a pipeline to offset the 2031 Dupixent patent expiry is "incorrect," with upcoming catalysts over the next 12 months set to build confidence, the analyst tells investors.
Morgan Stanley
Equal Weight -> Overweight
upgrade
$56 -> $58
2025-09-08
Reason
Morgan Stanley
Price Target
$56 -> $58
2025-09-08
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Sanofi to Overweight from Equal Weight with a price target of $58, up from $56. The firm believes the recent pullback in the shares brings an attractive entry point. The clarity on amlitelimab removes an overhang on the stock, and the equity story can shift from research and development execution back to Sanofi's earnings momentum in the near-term, the analyst tells investors in a research note. Morgan Stanley believes margin expansion in 2026 now looks possible for the company, supported by continued sales momentum.
Deutsche Bank
Emmanuel Papadakis
Hold
to
Buy
upgrade
2025-09-02
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
2025-09-02
upgrade
Hold
to
Buy
Reason
Deutsche Bank analyst Emmanuel Papadakis upgraded Sanofi to Buy from Hold with a price target of EUR 110, up from EUR 90. The firm expects the Phase 3 results for amlitelimab in atopic dermatitis to be positive. With a de-rated multiple, Sanofi shares offer an attractive risk/reward into the readout, the analyst tells investors in a research note.
JPMorgan
Richard Vosser
Neutral -> Overweight
upgrade
2025-08-08
Reason
JPMorgan
Richard Vosser
Price Target
2025-08-08
upgrade
Neutral -> Overweight
Reason
JPMorgan analyst Richard Vosser upgraded Sanofi to Overweight from Neutral with a price target of EUR 105, down from EUR 110. The firm sees positive risk/reward into the company's data readouts as it believes little pipeline value is being priced into the shares. Sanofi is undervalued even in the unlikely event of these assets being worth zero, the analyst tells investors in a research note. JPMorgan says Sanofi is trading at a 20% discount to the sector.
Deutsche Bank
Emmanuel Papadakis
Hold
downgrade
2025-08-05
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
2025-08-05
downgrade
Hold
Reason
Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Sanofi to EUR 90 from EUR 100 and keeps a Hold rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanofi SA (SNY.O) is 0.00, compared to its 5-year average forward P/E of 10.28. For a more detailed relative valuation and DCF analysis to assess Sanofi SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
10.28
Current PE
0.00
Overvalued PE
13.87
Undervalued PE
6.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
9.09
Current EV/EBITDA
8.32
Overvalued EV/EBITDA
9.79
Undervalued EV/EBITDA
8.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
2.58
Current PS
2.30
Overvalued PS
2.80
Undervalued PS
2.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 231.75% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SNY News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-12-02 (ET)
2025-12-02
11:30:00
FDA Drug Regulator Richard Pazdur to Retire at Month-End
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
PinnedSanofi Completes Acquisition of Vicebio, Enhancing Vaccine Development Capabilities
  • Acquisition Completed: On December 4, 2025, Sanofi announced the completion of its acquisition of Vicebio, which brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), significantly enhancing its competitiveness in the respiratory vaccine sector.
  • Technology Integration: By leveraging Vicebio's 'Molecular Clamp' technology, Sanofi expands its capabilities in vaccine design and development, not only increasing physician and patient choices for RSV and HMPV vaccines but also strengthening its strategic position in the vaccine market.
  • Market Impact: This acquisition allows Sanofi to add a non-mRNA vaccine to its pipeline, addressing the market's demand for diversified vaccine options, thereby enhancing its competitive edge in the global vaccine market.
  • Long-term Strategy: Sanofi is committed to driving its R&D-driven biopharmaceutical business through this acquisition, further solidifying its leadership in the global vaccine market and is expected to generate substantial long-term growth potential for the company.
[object Object]
Preview
9.0
11-27NASDAQ.COM
Biotech Stocks Await FDA Verdict in December 2025

  • National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.

  • World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.

  • HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.

  • Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.

[object Object]
Preview
2.0
11-26NASDAQ.COM
Kymera Approaches 52-Week Peak: Should Investors Buy, Sell, or Hold?

  • Stock Performance: Kymera Therapeutics, Inc. (KYMR) shares reached a 52-week high of $68.8, currently trading at $66.04, driven by optimism surrounding its lead candidate KT-621, which has surged 64.1% year-to-date compared to the industry’s 17.7% gain.

  • Pipeline Developments: KT-621, a first-in-class oral degrader for treating type 2 inflammation, is undergoing phase IIb trials for atopic dermatitis, with data expected by mid-2027. The company is also advancing a CDK2 molecular glue program in collaboration with Gilead Sciences.

  • Valuation Concerns: Despite promising developments, KYMR is considered overvalued with a price/book ratio of 4.99X, higher than the industry average. The consensus estimate for losses has widened for 2025 while narrowing for 2026.

  • Investment Recommendations: Current investors are advised to hold their shares, while potential investors should wait for a better entry point, especially given the recent changes in Sanofi's development strategy that may delay milestone payments for Kymera.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sanofi SA (SNY) stock price today?

The current price of SNY is 48.9 USD — it has decreased -1.59 % in the last trading day.

arrow icon

What is Sanofi SA (SNY)'s business?

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

arrow icon

What is the price predicton of SNY Stock?

Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sanofi SA (SNY)'s revenue for the last quarter?

Sanofi SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Sanofi SA (SNY)'s earnings per share (EPS) for the last quarter?

Sanofi SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Sanofi SA (SNY)'s fundamentals?

The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -1.39% over the past three months. During the same period, the stock price has changed by 7.88%.
arrow icon

How many employees does Sanofi SA (SNY). have?

Sanofi SA (SNY) has 84587 emplpoyees as of December 05 2025.

arrow icon

What is Sanofi SA (SNY) market cap?

Today SNY has the market capitalization of 118.78B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free